Commentary: Considerations on the pharmacotherapy of attention deficits and hyperactivity in children with autism and other pervasive developmental disorders

Journal of Autism and Developmental Disorders

Volumn 30, Issue 5, 2000, Pages 461-462

  Nicolson, Rob ^a   Castellanos, F Xavier ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ATTENTION; ATTENTION DEFICIT DISORDER; AUTISM; DEVELOPMENTAL DISORDER; HUMAN; IMPULSIVENESS; NOTE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; HUMANS; PSYCHOTROPIC DRUGS;

EID: 0033728714     PISSN: 01623257     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005511809545     Document Type: Note

References (8)

1. Stimulant drug effects in developmental disorders and hyperactivity - Toward a resolution of disparate findings
2. Stimulant drugs in the developmental disabilities revisited
3. Behavioral and cognitive measures used in psychopharmacological studies of infantile autism
4. Antipsychotics in children and adolescents
5. Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results
6. Does haloperidol block methylphenidate? Motivation or attention?
7. Stimulus over-selectivity in autism: A review of research
8. Use of methylphenidate in the treatment of children with autistic disorder